Xeris Biopharma Holdings
XERS
96 hedge funds and large institutions have $126M invested in Xeris Biopharma Holdings in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 24 reducing their positions, and 13 closing their positions.
335% more call options, than puts
Call options by funds: $11.3M | Put options by funds: $2.6M
77% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 13
50% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 24
12% more funds holding
Funds holding: 86 → 96 (+10)
2.23% less ownership
Funds ownership: 54.59% → 52.37% (-2.2%)
16% less capital invested
Capital invested by funds: $150M → $126M (-$23.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$939K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$727K |
| 3 |
Goldman Sachs
New York
|
+$700K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$675K |
| 5 |
Two Sigma Investments
New York
|
+$636K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Voloridge Investment Management
Jupiter,
Florida
|
-$1.42M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$1.21M |
| 3 |
MCM
Moore Capital Management
New York
|
-$1.04M |
| 4 |
AGM
Alpine Global Management
New York
|
-$1.01M |
| 5 |
DAM
Deltec Asset Management
New York
|
-$797K |
XERS Hedge Fund Activity: Q4 2020 in Review
96 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q4 2020, worth a combined $126M — down 16% from $150M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new XERS positions and 13 closed out — a net gain of 10 holders — while 36 added to existing stakes and 24 trimmed.
The largest buyer was Vanguard Group, adding an estimated $939K. The largest seller was Voloridge Investment Management, cutting an estimated $1.42M.
- 96 institutional investors held Xeris Biopharma Holdings (XERS) as of Q4 2020, up from 86 in Q3 2020.
- Funds reported $126M of Xeris Biopharma Holdings stock for Q4 2020, down 16% quarter-over-quarter.
- 23 funds opened new Xeris Biopharma Holdings positions in Q4 2020 and 13 closed out, a net change of +10 holders.
- The largest Xeris Biopharma Holdings buyer in Q4 2020 was Vanguard Group, an estimated $939K added.
- The largest Xeris Biopharma Holdings seller in Q4 2020 was Voloridge Investment Management, an estimated $1.42M sold.
Based on aggregated 13F filings for Q4 2020.